NCT06562361View on ClinicalTrials.gov

A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
MASHPSCFibrostenotic Crohn's DiseaseHealthy Volunteers
Interventions
DRUG

[68Ga]Ga-DOTA-Cys-ATH001

Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.

Trial Locations (3)

SE-171 64 S

RECRUITING

CTC Karolinska, Stockholm

SE-751 85

NOT_YET_RECRUITING

CTC Akademiska Uppsala University Hospital, Entrance 85, 2nd level, Uppsala

NOT_YET_RECRUITING

Section of Gastroenterology/Hepatology, Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

Antaros Medical
All Listed Sponsors
lead

Antaros Medical

INDUSTRY

NCT06562361 - A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups. | Biotech Hunter | Biotech Hunter